ArticleCA: a cancer journal for clinicians
Cancer statistics, 2026.
Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07550088 (A Single-Arm, Phase II Study Evaluating Combination Balstilimab Plus Botensilimab With AgenT-797 in Previously Treated Patients With pMMR Metastatic CRC With Liver Metastases), which is not on this map. Cited by 532 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm, Phase II Study Evaluating Combination Balstilimab Plus Botensilimab With AgenT-797 in Previously Treated Patients With pMMR Metastatic CRC With Liver Metastases
Who cites it
532 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Biomarker Detection of Lung Cancers Before Clinical Symptoms or the Use of Traditional Imaging Methods in the ITALUNG Trial.International journal of molecular sciences · 2026Trial
- The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.The Prostate · 2026Trial
- Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.Bioactive materials · 2027Article
- Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer.Cancer biology & therapy · 2026Review
- Cancer Survival at a Comprehensive Cancer Center Compared With Surveillance, Epidemiology, and End Results (SEER) Estimates.American journal of medicine open · 2026Article
- Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.Annals of medicine · 2026Article
- Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Reprogramming of cell death in gastric cancer: From molecular mechanisms to therapeutic potential (Review).International journal of molecular medicine · 2026Review
- Mitochondrial mechanisms underlying spatial immune phenotypes in non‑small cell lung cancer: Implications for ICI response and cold‑to‑hot tumor conversion (Review).Oncology reports · 2026Review
- Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer.Advances in radiation oncology · 2026Article
- OM-sqPCR enables one-step multiplex quantification of circulating small-RNA subclasses for colorectal cancer classification.iScience · 2026Article
- High Expression of Aurora Kinase A (AURKA) is Associated with Aggressive Tumor Biology and Therapeutic Response in ER+/HER2- Breast Cancer.Annals of surgical oncology · 2026Article
- Nanocarrier-Enabled Delivery of Glucosinolates for Skin Cancer Prevention and Therapy.The AAPS journal · 2026Review
- Targeting oral cancer with curcumin and its structural analogs: molecular mechanisms, pharmacokinetic optimization, and clinical translation.Archives of pharmacal research · 2026Review
- Article
- Porphyrin-copper (II) covalent organic framework nanoplatform with intrinsic bifunctional photodynamic and chemodynamic activities for synergistic multimodal cancer therapy.Materials today. Bio · 2026Article
- Blueprint for adapting the cardiac rehabilitation model for oncology patients with cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
- Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.Oncogene · 2026Article
- Associations of CT-Derived Skeletal Muscle Index and Density With Postoperative Outcomes Following Colorectal Cancer Surgery.Journal of cachexia, sarcopenia and muscle · 2026Article
472 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5-year relative survival, which reached a milestone 70% for diagnoses during 2015-2021 overall, 69% for regional-stage disease, and 35% for distant-stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid-1990s. People with high-mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life-saving cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.